Title Page

Contents

Abstract 10

Ⅰ. INTRODUCTION 12

Ⅱ. MATERIALS AND METHODS 14

1. Experimental animal model and Injection group setting 14

2. Total RNA extraction and microarray analysis 15

3. Principal component analysis (PCA) analysis 16

4. Differential expressed genes (DEGs) analysis 17

5. Hierarchical Clustering Analysis 18

6. Gene enrichment analysis 19

Ⅲ. RESULTS 20

1. Differentiate according to EPO or UCB or UCB+EPO combination treatment. 20

2. Approach 1 - The analysis flow of the whole gene and the DEGs between each group were calculated. 22

3. Genes specifically expressed in comparison of each group were identified. 30

4. Upregulation of co-administered EPO and UCB was confirmed by gene ontology. 32

5. Approach 2 - The flow of gene analysis excluding immune-related genes and the DEGs between each group was calculated. 35

6. Genes specifically expressed in comparison of each group were identified. 43

7. Upregulation of co-administered EPO and UCB was confirmed by gene ontology. 45

Ⅳ. DISCUSSION 48

Ⅴ. CONCLUSION 51

REFERENCES 52

ABBREVIATIONS 57

ABSTRACT IN KOREAN 58

Table 1. sham and HI's expression levels and |log₂FC| of top50 24

Table 2. HI+EPO and HI's expression levels and |log₂FC| of top50 25

Table 3. HI+UCB and HI's expression levels and |log₂FC| of top50 26

Table 4. HI+EPO+UCB and HI's expression levels and |log₂FC| of top50 27

Table 5. HI+EPO+UCB and HI+EPO's expression levels and |log₂FC| of top50 28

Table 6. HI+EPO+UCB and HI+UCB's expression levels and |log₂FC| of top50 29

Table 7. Gene ontology pathways of G6 group 34

Table 8. sham and HI's expression levels and |log₂FC| of top50 37

Table 9. HI+EPO and HI's expression levels and |log₂FC| of top50 38

Table 10. HI+UCB and HI's expression levels and |log₂FC| of top50 39

Table 11. HI+EPO+UCB and HI's expression levels and |log₂FC| of top50 40

Table 12. HI+EPO+UCB and HI+EPO's expression levels and |log₂FC| of top50 41

Table 13. HI+EPO+UCB and HI+UCB's expression levels and |log₂FC| of top50 42

Table 14. Gene ontology pathways of G5 group 47

Figure 1. Changes in animal models after administration of EPO and UCB. 21

Figure 2. Workflow of total genes analysis 22

Figure 3. Venn diagram of gene in each group after DEGs. 31

Figure 4. Heatmap of gene expression level pattern in each group 33

Figure 5. Workflow of analysis after immune-related genes exclusion 35

Figure 6. Venn diagram of gene in each group after DEGs. 44

Figure 7. Heatmap of gene expression level pattern in each group 46